Neurogene Inc. (NGNE) Investor Relations Documents

Neurogene Inc. (NGNE) investor relations documents from the company's IR site: 2 presentations, 36 press releases; latest deck 2026-08-11. Read in-app with summaries. First-party data.

Neurogene Corporate Presentation August 2026: Neurogene's NGN-401 shows strong efficacy in Rett Syndrome, with 100% of patients gaining developmental milestones in trials, advancing towards BLA submission.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-11PresentationNeurogene Corporate Presentation August 2026
2026-08-11Press releaseNeurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates
2026-08-04Press releaseNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-06Press releaseNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-01Press releaseNeurogene Inc. Announces Pricing of $125 Million Public Offering
2026-06-30Press releaseNeurogene Inc. Announces Proposed Public Offering
2026-06-29PresentationNGN-401 Phase 1/2 Clinical Data Update June 2026
2026-06-29Press releaseNeurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
2026-06-13Press releasePDF Version
2026-06-09Press releasePDF Version
2026-06-08Press releaseNeurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome
2026-06-07Press releasePDF Version
2026-06-06Press releasePDF Version
2026-06-02Press releaseNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-12Press releaseNeurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates
2026-05-12Press releaseNeurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene
2026-05-06Press releasePDF Version
2026-05-06Press releaseNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-04-28Press releasePDF Version
2026-04-28Press releaseNeurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy
2026-04-20Press releasePDF Version
2026-04-20Press releaseNeurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.D., to Board of Directors
2026-04-08Press releasePDF Version
2026-04-08Press releaseNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Press releaseNeurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates
2026-03-11Press releasePDF Version
2026-03-03Press releasePDF Version
2026-03-03Press releaseNeurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-02-26Press releasePDF Version
2026-02-26Press releaseNeurogene Announces FDA Breakthrough Therapy Designation for NGN-401 Gene Therapy for Rett Syndrome
2026-02-05Press releasePDF Version
2026-02-05Press releaseNeurogene to Participate in Upcoming Investor Conferences
2026-02-04Press releasePDF Version
2026-02-04Press releaseNeurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-01-12Press releasePDF Version
2026-01-12Press releaseNeurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene
2026-01-05Press releasePDF Version
2026-01-05Press releaseNeurogene to Participate in the 44th Annual J.P. Morgan Healthcare Conference

NGNE overview · NGNE earnings · NGNE financials · NGNE KPIs · NGNE documents · NGNE ownership · NGNE peers

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.